Q32 Bio
QTTB
50 hedge funds and large institutions have $455M invested in Q32 Bio in 2018 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 24 increasing their positions, 7 reducing their positions, and 10 closing their positions.
243% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 7
9% more capital invested
Capital invested by funds: $419M → $455M (+$36.8M)
0.09% less ownership
Funds ownership: 3.06% → 2.97% (-0.09%)
6% less funds holding
Funds holding: 53 → 50 (-3)
30% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 10
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
+$9.74M |
| 2 |
CC
Casdin Capital
New York
|
+$4.43M |
| 3 |
RI
RTW Investments
New York
|
+$3.93M |
| 4 |
GTP
Global Thematic Partners
New York
|
+$2.54M |
| 5 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$1.95M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$19M |
| 2 |
MC
Maverick Capital
Dallas,
Texas
|
-$10.5M |
| 3 |
VC
Vivo Capital
Palo Alto,
California
|
-$4.72M |
| 4 |
JGC
J. Goldman & Co
New York
|
-$3.13M |
| 5 |
Alyeska Investment Group
Chicago,
Illinois
|
-$2.04M |
QTTB Hedge Fund Activity: Q3 2018 in Review
50 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Q32 Bio (QTTB) for Q3 2018, worth a combined $455M — up 8.8% from $419M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of QTTB and 7 opened new positions — a net loss of 3 holders — while 7 trimmed existing stakes and 24 added.
The largest buyer was JP Morgan Chase, adding an estimated $9.74M. The largest seller was Fidelity Investments, cutting an estimated $19M.
- 50 institutional investors held Q32 Bio (QTTB) as of Q3 2018, down from 53 in Q2 2018.
- Funds reported $455M of Q32 Bio stock for Q3 2018, up 8.8% quarter-over-quarter.
- 7 funds opened new Q32 Bio positions in Q3 2018 and 10 closed out, a net change of -3 holders.
- The largest Q32 Bio buyer in Q3 2018 was JP Morgan Chase, an estimated $9.74M added.
- The largest Q32 Bio seller in Q3 2018 was Fidelity Investments, an estimated $19M sold.
Based on aggregated 13F filings for Q3 2018.